Trials / Completed
CompletedNCT02966795
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6 infection, with or without compensated cirrhosis respectively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glecaprevir/Pibrentasvir | Fixed-dose combination tablets taken orally once a day. |
Timeline
- Start date
- 2017-01-25
- Primary completion
- 2018-06-06
- Completion
- 2018-08-29
- First posted
- 2016-11-17
- Last updated
- 2021-07-30
- Results posted
- 2019-07-10
Locations
25 sites across 9 countries: United States, Australia, Belgium, Canada, France, New Zealand, Singapore, South Africa, Vietnam
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02966795. Inclusion in this directory is not an endorsement.